Basilea Pharmaceutica AG
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Basilea Pharmaceutica AG generated cash of $14,245,000, which is more than the previous year. Cash used in financing activities reached the amount of -$57,305,000 last year. Net change in cash is therefore -$44,245,000.
Cash Flow
| 2014 | -71.46M | 83.69M | 24.86M |
|---|---|---|---|
| 2015 | -67.78M | 17.09M | 208.06M |
| 2016 | -75.00M | 1.21M | 411K |
| 2017 | 19.01M | -60.94M | 2.63M |
| 2018 | -79.21M | 59.39M | -5.98M |
| 2019 | -63.83M | -404K | 1.30M |
| 2020 | -54.13M | -34.96M | 45.06M |
| 2021 | -32.02M | 3.57M | 16.64M |
| 2022 | 7.05M | 91.64M | -45.24M |
| 2023 | 14.24M | -1.03M | -57.30M |
BSLN.SW Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 108.56M | 54.95M | 55.60M | 54.52M | 38.30M | 200.72M | 239.03M | 313.06M | 156.12M | 118.89M |
Operating activities | ||||||||||
Net income | 10.45M | 12.14M | -6.83M | -14.72M | -22.42M | -31.35M | -19.36M | -51.28M | -61.60M | -41.54M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 3.47M | 3.09M | 2.45M | 2.29M | 1.63M | 1.75M | 1.89M | 2.21M | 2.32M | 2.29M |
Stock-based compensation expense | 4.76M | 3.59M | 4.32M | 3.52M | 3.04M | 0 | 4.62M | 8.02M | 9.3M | 5.92M |
| Deferred income tax benefit | 4.76M | 3.59M | 4.32M | 3.52M | 3.04M | 0 | 4.62M | 8.02M | 9.3M | 5.92M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 3.45M | 2.58M | -32.06M | -4.12M | 6.45M | 1.05M | -2.27M | -1.09M | -383K | 2.73M |
Inventories | -2.16M | -1.46M | -1.59M | -2.61M | -4.14M | 741K | -45K | -6.85M | -4.79M | -4.84M |
Accounts payable | 5.65M | -10.42M | -2.53M | 6.39M | 378K | 2.05M | 2.5M | 764K | -1.01M | 0 |
Cash generated by operating activities | 14.24M | 7.05M | -32.02M | -54.13M | -63.83M | -79.21M | 19.01M | -75.00M | -67.78M | -71.46M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | -35M | -81.02M | -50M | 0 | -60M | -50M | -81.6M | -90M |
Investments In Property Plant And Equipment | -813K | -3.30M | -860K | -2.26M | -404K | -419K | -711K | -394K | -1.00M | -1.24M |
Acquisitions Net | 0 | 0 | -1.58M | 18.32M | 110K | 0 | 5K | 7K | 9K | -85M |
Cash generated by investing activities | -1.03M | 91.64M | 3.57M | -34.96M | -404K | 59.39M | -60.94M | 1.21M | 17.09M | 83.69M |
Financing activities | ||||||||||
Common Stock Issued | 2.39M | 4.42M | 44.10M | 4.80M | 1.30M | 249K | 2.63M | 411K | 13.37M | 24.86M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -381K | 0 | -4.25M | 0 | 0 | -6.23M | 0 | 0 | 0 | 0 |
Repayments of term debt | -59.31M | 73.87M | -23.21M | -40.25M | 0 | 0 | 0 | 0 | 194.68M | 0 |
Cash used in financing activities | -57.30M | -45.24M | 16.64M | 45.06M | 1.30M | -5.98M | 2.63M | 411K | 208.06M | 24.86M |
Net Change In Cash | -44.24M | -18.38M | -654K | 1.08M | 16.21M | -26.81M | -38.30M | -74.03M | 156.93M | 37.22M |
Cash at end of period | 64.32M | 36.56M | 54.95M | 55.60M | 54.52M | 173.90M | 200.72M | 239.03M | 313.06M | 156.12M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |